治疗阻塞性肥厚型心肌病的两种心肌酶抑制剂。
IF 12.8
Q1 MEDICINE, RESEARCH & EXPERIMENTAL
引用次数: 0
摘要
阻塞性肥厚型心肌病治疗进展的一个关键领域是心脏肌球蛋白抑制剂的出现，其中mavacamten和aficamten代表了第一和第二种分子。我们总结了主要的研究证据，包括研究这些分子的各种临床试验之间的许多相似之处和潜在差异。本文章由计算机程序翻译，如有差异，请以英文原文为准。
Two cardiac myosin inhibitors in the treatment of obstructive hypertrophic cardiomyopathy.
A key area of therapeutic progress in obstructive hypertrophic cardiomyopathy revolves around the emergence of cardiac myosin inhibitors, of which mavacamten and aficamten represent the first and second molecules. We summarize the key research evidence, including many similarities and potential differences between various clinical trials studying these molecules.
求助全文
通过发布文献求助，成功后即可免费获取论文全文。
去求助
来源期刊
Med
MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
17.70
自引率
0.60%
发文量
102
期刊介绍：
Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically.
Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
